TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+46.64%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$960M
AUM Growth
+$960M
(-11%)
Cap. Flow
-$331M
Cap. Flow
% of AUM
-34.51%
Top 10 Holdings %
Top 10 Hldgs %
38.43%
Holding
146
New
23
Increased
17
Reduced
40
Closed
47
Top Buys
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
Outlook Therapeutics
OTLK
|
$19.3M |
| 3 |
Immunome
IMNM
|
$17.8M |
| 4 |
Applied Therapeutics
APLT
|
$15.2M |
| 5 |
Evolus
EOLS
|
$14.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 98.03% |
| 2 | Technology | 0.94% |
| 3 | Communication Services | 0.51% |
| 4 | Real Estate | 0.32% |
| 5 | Financials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Liquidia Corp
LQDA
$2.52B
| $2.21M | 0.23% |
+150,000
| New | +$2.21M |
|
77
Kura Oncology
KURA
$732M
| $2.13M | 0.22% |
+100,000
| New | +$2.13M |
|
78
Passage Bio
PASG
$22.6M
| $2.03M | 0.21% |
75,000
-45,000
| -38% | -$1.22M |
|
|
FLG
79
Flagstar Financial, Inc.
FLG
$5.33B
| $1.95M | 0.2% |
202,200
-333,333
| -62% | -$3.22M |
|
80
Aligos Therapeutics
ALGS
$75.1M
| $1.62M | 0.17% |
66,000
-21,594
| -25% | -$529K |
|
|
ENZ
81
DELISTED
Enzo Biochem, Inc.
ENZ
| $1.6M | 0.17% |
1,260,013
-439,987
| -26% | -$559K |
|
82
TG Therapeutics
TGTX
$5.03B
| $1.52M | 0.16% |
100,000
| – | – |
|
83
Atara Biotherapeutics
ATRA
$88.7M
| $1.3M | 0.14% |
+75,197
| New | +$1.3M |
|
84
Seer Inc
SEER
$114M
| $1.28M | 0.13% |
+674,125
| New | +$1.28M |
|
85
InflaRx
IFRX
$117M
| $1.18M | 0.12% |
769,065
-1,104,688
| -59% | -$1.7M |
|
|
TECX
86
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $1.09M | 0.11% |
+71,067
| New | +$1.09M |
|
87
Acumen Pharmaceuticals
ABOS
$82.4M
| $1,000K | 0.1% |
246,895
| – | – |
|
|
RVNC
88
DELISTED
Revance Therapeutics, Inc.
RVNC
| $984K | 0.1% |
+200,000
| New | +$984K |
|
|
ATYR
89
aTyr Pharma
ATYR
$560M
| $919K | 0.1% |
471,134
| – | – |
|
90
Seres Therapeutics
MCRB
$162M
| $702K | 0.07% |
45,356
-44,288
| -49% | -$686K |
|
91
uniQure
QURE
$954M
| $696K | 0.07% |
133,921
-466,079
| -78% | -$2.42M |
|
|
EGRX
92
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $623K | 0.06% |
118,857
| – | – |
|
93
Kezar Life Sciences
KZR
$28.5M
| $621K | 0.06% |
68,894
+38,227
| +125% | +$345K |
|
94
Journey Medical
DERM
$187M
| $510K | 0.05% |
+138,625
| New | +$510K |
|
|
MOLN
95
Molecular Partners
MOLN
$139M
| $420K | 0.04% |
100,000
| – | – |
|
96
NextCure
NXTC
$13.3M
| $322K | 0.03% |
12,043
-26,951
| -69% | -$721K |
|
97
Amylyx Pharmaceuticals
AMLX
$877M
| $284K | 0.03% |
100,000
-100,000
| -50% | -$284K |
|
98
Erasca
ERAS
$406M
| $206K | 0.02% |
100,000
-50,000
| -33% | -$103K |
|
99
Relmada Therapeutics
RLMD
$48.8M
| $1.78K | ﹤0.01% |
+382
| New | +$1.78K |
|
100
ServisFirst Bancshares
SFBS
$4.77B
| – | – |
-30,000
| Closed | -$2M |
|